Hepatitis C virus infection can affect lymphoproliferative disorders only as a cofactor for epstein-barr virus in liver transplant recipients: PTLD. Int survey

Experimental and Clinical Transplantation

Volumn 10, Issue 2, 2012, Pages 141-147

  Khedmat, Hossein ^a   Taheri, Saeed ^b  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Taheri Medical Research Group   (Iran)

Author keywords

EBV; Hepatitis C virus; Liver transplant; Posttransplant lymphoproliferative disorders; PTLD

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BEHAVIORAL SCIENCE; DATA ANALYSIS; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS INFECTION; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT REJECTION; HEPATITIS C; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; LYMPHOMA; LYMPHOMA CELL; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; POSTTTRANSPLANTATION LYMPHOPROLIFERATIVE DISEASE; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW;

ADULT; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HEALTH SURVEYS; HEPATITIS C, CHRONIC; HUMANS; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84859307766     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: 10.6002/ect.2011.0114     Document Type: Article

References (66)

1. Penn I, Hammond W, Brettschneider L, Starzl TE. Malignant lymphomas in transplantation patients. Transplant Proc. 1969;1(1):106-112.
2. Mamzer-Bruneel MF, Bourquelot P, Hermine O, Legendre C, Kreis H. Treatment and prognosis of post-transplant lymphoproliferative disease. Ann Transplant. 1997;2(4):42-48.
3. Boubenider S, Hiesse C, Goupy C, Kriaa F, Marchand S, Charpentier B. Incidence and consequences of post-transplantation lymphoproliferative disorders. J Nephrol. 1997;10(3):136-145.
4. Swinnen LJ. Diagnosis and treatment of transplant-related lymphoma. Ann Oncol. 2000;11 (Suppl 1):45-48.
5. Basgoz N, Preiksaitis JK. Post-transplant lymphoproliferative disorder. Infect Dis Clin North Am. 1995;9(4):901-923.
6. Hanto DW. Classification of Epstein-Barr virus-associated posttransplant lymphoproliferative diseases: implications for understanding their pathogenesis and developing rational treatment strategies. Annu Rev Med. 1995;46:381-394.
7. Penn I. Posttransplantation de novo tumors in liver allograft recipients. Liver Transpl Surg. 1996;2(1):52-59.
8. Mucha K, Foroncewicz B, Niemczyk K, et al. Tonsil enlargement after liver transplantation in adults--reason enough for tonsillectomy? Two cases of tonsillar posttransplantation lymphoproliferative disease. Liver Transpl. 2007;13(6):918-923.
9. Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004;4(2):222-230.
10. Aucejo F, Rofaiel G, Miller C. Who is at risk for post-transplant lymphoproliferative disorders (PTLD) after liver transplantation? J Hepatol. 2006;44(1):19-23.
11. Yang J, Tao Q, Flinn IW, et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood. 2000;96(13):4055-4063.
12. Young L, Alfieri C, Hennessy K, et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med. 1989;321(16):1080-1085.
13. Pawlotsky JM, Roudot-Thoraval F, Simmonds P, et al. Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes. Ann Intern Med. 1995;122(3):169-173.
14. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992;327(21):1490-1495.
15. Dammacco FS, Sansonno D, Piccoli C, Tucci FA, Racanelli V. The cryoglobulins: an overview. Eur J Clin Invest. 2001;31(7):628-638.
16. Ferri C, Monti M, La Civita L, et al. Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. Blood. 1993;82(12):3701-3704.
17. Gumber SC, Chopra S. Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med. 1995;123(8):615-620.
18. Misiani R, Bellavita P, Fenili D, et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med. 1992;117(7):573-577.
19. Franzin F, Efremov DG, Pozzato G, Tulissi P, Batista F, Burrone OR. Clonal B-cell expansions in peripheral blood of HCV- infected patients. Br J Haematol. 1995;90(3):548-552.
20. Sansonno D, Cornacchiulo V, Iacobelli AR, Gatti P, Distasi M, Dammacco F. Hepatitis C virus infection and clonal B-cell expansion. Clin Exp Rheumatol. 1996;14(Suppl 14):45-50.
21. McLaughlin K, Wajstaub S, Marotta P, et al. Increased risk for posttransplant lymphoproliferative disease in recipients of liver transplants with hepatitis C. Liver Transpl. 2000;6(5):570-574.
22. Avolio AW, Agnes S, Barbarino R, et al. Posttransplant lymphoproliferative disorders after liver transplantation: analysis of early and late cases in a 255 patient series. Transplant Proc. 2007;39(6):1956-1960.
23. Duvoux C, Pageaux GP, Vanlemmens C, et al. Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients. Transplantation. 2002;74(8):1103-1109.
24. Capello D, Rossi D, Gaidano G. Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis. Hematol Oncol. 2005;23(2):61-67.
25. Norin S, Kimby E, Ericzon BG, et al. Posttransplant lymphoma-a single-center experience of 500 liver transplantations. Med Oncol. 2004;21(3):273-284.
26. Hézode C, Duvoux C, Germanidis G, et al. Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation. Hepatology. 1999;30(3):775-778.
27. Buadi FK, Heyman MR, Gocke CD, et al. Treatment and outcomes of post-transplant lymphoproliferative disease: a single institution study. Am J Hematol. 2007;82(3):208-214.
28. Zimmermann T, Hoppe-Lotichius M, Tripkovic V, et al. Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for Post-Transplant Lymphoproliferative Disease (PTLD). Eur J Intern Med. 2010;21(3):208-215.
29. Lorenzini S, Andreone P, Gramenzi A, et al. Posttransplant lymphoproliferative disorders in liver transplanted patients: a report of four cases. Transplant Proc. 2006;38(5):1477-1480.
30. Timuraǧaoǧlu A, Uǧur-Bilgin A, Colak D, et al. Posttransplant lymphoproliferative disorders in transplant recipients. Transplant Proc. 2006;38(2):641-645.
31. Ziarkiewicz-Wróblewska B, Górnicka B, Suleiman W, et al. Posttransplant lymphoproliferative disorder: morphological picture and diagnostic difficulties. Transplant Proc. 2006;38(1):168-172.
32. Niedobitek G, Mutimer DJ, Williams A, et al. Epstein-Barr virus infection and malignant lymphomas in liver transplant recipients. Int J Cancer. 1997;73(4):514-520.
33. Nuckols JD, Baron PW, Stenzel TT, et al. The pathology of liverlocalized post-transplant lymphoproliferative disease: a report of three cases and a review of the literature. Am J Surg Pathol. 2000;24(5):733-741.
34. Baron PW, Heneghan MA, Suhocki PV, et al. Biliary stricture secondary to donor B-cell lymphoma after orthotopic liver transplantation. Liver Transpl. 2001;7(1):62-67.
35. Ben-Ari Z, Amlot P, Lachmanan S, Tur-Kaspa R, Rolles K, Burroughs AK. Posttransplantation lymphoproliferative disorder in liver recipients: characteristics, management, and outcome. Liver Transpl Surg. 1999;5(3):184-191.
36. Koh BY, Rosenthal P, Medeiros LJ, et al. Posttransplantation lymphoproliferative disorders in pediatric patients undergoing liver transplantation. Arch Pathol Lab Med. 2001;125(3):337-343.
37. Baccarani U, Piselli P, Serraino D, et al. Comparison of de novo tumours after liver transplantation with incidence rates from Italian cancer registries. Dig Liver Dis. 2010;42(1):55-60.
38. Bianchi E, Pascual M, Nicod M, Delaloye AB, Duchosal MA. Clinical usefulness of FDG-PET/CT scan imaging in the management of posttransplant lymphoproliferative disease. Transplantation. 2008;85(5):707-712.
39. Burra P, Buda A, Livi U, et al. Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection? Eur J Gastroenterol Hepatol. 2006;18(10):1065-1070.
40. Lemoine A, Pham P, Azoulay D, et al. Detection of gammopathy by serum protein electrophoresis for predicting and managing therapy of lymphoproliferative disorder in 911 recipients of liver transplants. Blood. 2001;98(5):1332-1338.
41. Cano B, Sanchez G, Montoliu G, et al. Imaging of liver-localized posttransplantion lymphoproliferative disease as complication of liver transplantion. European J Radiol Extra. 2004;49:61-66.
42. Dhillon MS, Rai JK, Gunson BK, Olliff S, Olliff J. Post-transplant lymphoproliferative disease in liver transplantation. Br J Radiol. 2007;80(953):337-346.
43. Sun X, Peterson LC, Gong Y, Traynor AE, Nelson BP. Post-transplant plasma cell myeloma and polymorphic lymphoproliferative disorder with monoclonal serum protein occurring in solid organ transplant recipients. Mod Pathol. 2004;17(4):389-394.
44. Pham H, Lemoine A, Salvucci M, et al. Occurrence of gammopathies and lymphoproliferative disorders in liver transplant recipients randomized to tacrolimus (FK506)- or cyclosporine-based immunosuppression. Liver Transpl Surg. 1998;4(2):146-151.
45. Nagarsheth NP, Kalir T, Rahaman J. Post-transplant lymphoproliferative disorder of the cervix. Gynecol Oncol. 2005;97(1):271-275.
46. Hsi ED, Singleton TP, Swinnen L, Dunphy CH, Alkan S. Mucosaassociated lymphoid tissue-type lymphomas occurring in posttransplantation patients. Am J Surg Pathol. 2000;24(1):100-106.
47. Kogan-Liberman D, Burroughs M, Emre S, Moscona A, Shneider BL. The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience. J Pediatr Gastroenterol Nutr. 2001;33(4):445-449.
48. Aseni P, Vertemati M, De Carlis L, et al. De novo cancers and posttransplant lymphoproliferative disorder in adult liver transplantation. Pathol Int. 2006;56(11):712-715.
49. McCormack L, Hany TI, Hübner M, et al. How useful is PET/CT imaging in the management of post-transplant lymphoproliferative disease after liver transplantation? Am J Transplant. 2006;6(7):1731-1736.
50. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet. 1993;342(8886/8887):1514-1516.
51. De Rosa G, Gobbo ML, De Renzo A, et al. High prevalence of hepatitis C virus infection in patients with B-cell lymphoproliferative disorders in Italy. Am J Hematol. 1997;55(2):77-82.
52. Persico M, De Renzo A, Persico E, Torella D, Rotoli B, Torella R. Chronic liver disease and lymphoproliferative disorders in HCVpositive patients: a working hypothesis. J Hepatol. 1998;29(5):857-858.
53. Ferri C, Caracciolo F, Zignego AL, et al. Hepatitis C virus infection in patients with non-Hodgkin's lymphoma. Br J Haematol. 1994;88(2):392-394.
54. Cucuianu A, Patiu M, Duma M, et al. Hepatitis B and C virus infection in Romanian non-Hodgkin's lymphoma patients. Br J Haematol. 1999;107(2):353-356.
55. Kuniyoshi M, Nakamuta M, Sakai H, et al. Prevalence of hepatitis B or C virus infections in patients with non-Hodgkin's lymphoma. J Gastroenterol Hepatol. 2001;16(2):215-219.
56. Ivanovski M, Silvestri F, Pozzato G et al. Somatic hypermutation, clonal diversity, and preferential expression of the VH 51p1/VL kv325 immunoglobulin gene combination in hepatitis C virusassociated immunocytomas. Blood. 1998;91(7):2433-2442.
57. Silvestri F, Baccarani M. Hepatitis C virus-related lymphomas. Br J Haematol. 1997;99(3):475-480.
58. Aljurf MD, Owaidah TW, Ezzat A, Ibrahim E, Tbakhi A. Antigenand/ or immune-driven lymphoproliferative disorders. Ann Oncol. 2003;14(11):1595-1606.
59. Lerat H, Rumin S, Habersetzer F, et al. In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load, viral genotype, and cell phenotype. Blood. 1998;91(10):3841-3849.
60. De Vita S, Sansonno D, Dolcetti R, et al. Hepatitis C virus within a malignant lymphoma lesion in the course of type II mixed cryoglobulinemia. Blood. 1995;86(5):1887-1892.
61. Sansonno D, Lotesoriere C, Cornacchiulo V, et al. Hepatitis C virus infection involves CD34(+) hematopoietic progenitor cells in hepatitis C virus chronic carriers. Blood. 1998;92(9):3328-3337.
62. Ferri C, La Civita L, Monti M, et al. Can type C hepatitis infection be complicated by malignant lymphoma? Lancet. 1995;346(8987):1426-1427.
63. Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med. 1994;330(11):751-756.
64. Dammacco F, Sansonno D, Han JH, et al. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood. 1994;84(10):3336-3343.
65. Khedmat H, Alavian S, Taheri S. Significance of Epstein-Barr virus infection in the outcome of renal transplant patients with lymphoproliferative disorders. Ann Transplant. 2010;15(2):40-44.
66. Izadi M, Taheri S. Significance of in situ hybridization results for EBV-encoded RNA in post-transplantation lymphoproliferative disorder setting: report from the PTLD. Int Survey. Ann Transplant. 2010;15(4):102-109.